Research Analysts’ Recent Ratings Updates for Prime Medicine (PRME)

Prime Medicine (NASDAQ: PRME) recently received a number of ratings updates from brokerages and research firms:

• 8/18/2026 – Prime Medicine is now covered by BMO Capital Markets. They set an “outperform” rating and a $9.00 price target on the stock.
• 8/18/2026 – Prime Medicine is now covered by BMO Capital Markets. They set an “outperform” rating and a $9.00 price target on the stock.
• 8/10/2026 – Prime Medicine had its “buy” rating reaffirmed by HC Wainwright. They now have a $8.00 price target on the stock.
• 8/8/2026 – Prime Medicine was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 7/8/2026 – Prime Medicine had its “buy” rating reaffirmed by TD Cowen.
• 6/29/2026 – Prime Medicine was given a new $8.00 price target by New Street Research.
• 6/29/2026 – Prime Medicine was upgraded by HC Wainwright from “neutral” to “buy”. They now have a $8.00 price target on the stock.

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.